Fig 6.

Efficacy of lysozymes combined with 75 μg intraperitoneal tobramycin (Tob) (n = 10 mice per group). One mouse each from the groups treated with PBS, tobramycin only, and hLYS and tobramycin exhibited acute morbidity and was removed prior to study completion. (A) Numbers of lung P. aeruginosa CFU following treatment with tobramycin alone, tobramycin combined with 100 μg wild-type hLYS, or tobramycin combined with 100 μg engineered variant 2-3-7 (ANOVA, P = 0.005); (B) analogous BALF immune cell concentrations (ANOVA, P = 0.170). The means ± SEMs are indicated. *, P < 0.05 compared with the PBS control group.